Dexmedetomidine through to 72 hours cut complications in high-risk elderly surgery

Design

multicentre, randomised, placebo-controlled superiority trial with central randomisation

Population

272 patients aged ≥60 with revised cardiac risk index ≥3 undergoing major non-cardiac surgery; median age 70 and 69 years

Primary outcome

major postoperative complications across seven organ systems within 30 days

Effect

38.2% (52/136) vs 52.9% (72/136); relative risk 0.722 (95% CI 0.554–0.942), p=0.015; stay 1 day shorter (95% CI −2 to 0)

Patients over 60 with a revised cardiac risk index of 3 or more going to major non-cardiac surgery have a high rate of complications spanning several organ systems, and the inflammatory response to surgery is the proposed common driver. This multicentre superiority trial randomised 272 such patients to dexmedetomidine — a 0.5 µg/kg load then 0.3 µg/kg/h intraoperatively, continued at 2 µg/h for 72 hours alongside sufentanil patient-controlled analgesia — or to saline with sufentanil alone.

Major complications within 30 days, counted across neurologic, cardiovascular, renal, pulmonary, coagulation, infectious and gastrointestinal systems, occurred in 38.2% of the dexmedetomidine group and 52.9% of controls: relative risk 0.722 (95% CI 0.554–0.942, p=0.015). Postoperative stay was a day shorter. The peak neutrophil-to-lymphocyte ratio in the first three days was lower by 2.1 (95% CI −4.1 to −0.3), consistent with the proposed inflammatory mechanism. Drug-related adverse events did not differ, and other secondary outcomes — pain, sleep quality, cost — were comparable.

Two things temper this for a nephrologist. The primary outcome is a composite across seven organ systems, so a renal-specific effect is not established and should not be inferred; the abstract does not break out acute kidney injury. And 272 patients with 124 events is a modest trial for a composite this broad. But the direction, the dose-response plausibility and the inflammatory marker all point the same way, and the intervention is a drug already in the anaesthetic room.

• This is a composite across seven organ systems — do not quote it as a kidney protection result.
• The regimen ran to 72 hours postoperatively, not just intraoperatively; a bolus at induction is not what was tested.
• Bradycardia and hypotension are the expected effects and need monitoring for the full 72 hours, which requires a staffed bed.
• Patients had a revised cardiac risk index of 3 or more — this does not apply to average-risk surgical patients.
• Dexmedetomidine is available and affordable in India; the constraint is the 72-hour monitored infusion, not the drug.

Why it matters

It offers a modifiable perioperative intervention for the patients most likely to develop kidney injury after surgery, even if this trial cannot show that it prevented it.

Don't overread it

A composite across seven organ systems in 272 patients — this does not establish that dexmedetomidine prevents postoperative acute kidney injury.

The statistics, in plain English

A relative risk of 0.722 with an upper bound of 0.942 is a real but not commanding result — and it comes from a composite endpoint, where a large effect on one common component can carry the whole. With 52 and 72 events, the individual organ systems have far too few events each to show which one moved. The one-day shorter stay has a confidence interval of −2 to 0 days, meaning the data are compatible with no difference at all. The neutrophil-to-lymphocyte ratio result supports the mechanism but is a laboratory marker, not an outcome.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.